Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1111-1121

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization

By  

Oncology, Vol. 91, Iss. 6, 2016-10 ,pp. : 317-330

Karger

Access to resources Recommend Favorite

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602

By Sato Yozo  

Upsala Journal of Medical Sciences, Vol. 118, Iss. 1, 2013-03 ,pp. : 16-22

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 192-200

Karger

Access to resources Recommend Favorite

Does diffusion‐weighted imaging improve therapy response evaluation in patients with hepatocellular carcinoma after radioembolization? comparison of MRI using Gd‐EOB‐DTPA with and without DWI

By  

JOURNAL OF MAGNETIC RESONANCE IMAGING, Vol. 42, Iss. 3, 2015-09 ,pp. : 818-827

John Wiley & Sons Inc

Access to resources Recommend Favorite